CME/CE-certified, MOC-eligible Webinars
Step 1: Click here to create an account, or login if you already have an account.
Step 2: Click on the FAOD webinar course to return to this page or if you are already logged in, proceed to Step 3.
Step 3: Click here to complete your registration.
DATES AND TIMES
Tuesday, May 12, 2020
12:00 Noon - 1:00 PM EST (11:00 AM - 12:00 Noon CST / 9:00 - 10:00 AM PST)
Program Faculty: Melanie Gillingham, PhD, RD; Jerry Vockley, MD, PhD
Long-chain fatty acid oxidation disorders (LC-FAODs) are rare; however, these conditions continue to be associated with high mortality and suboptimal disease control. Reasons include: 1) a lack of agreement regarding LC-FAOD treatment, 2) a lack of published guidelines, 3) treatment nonadherence among patients, 4) confusion regarding how to assess and interpret LC-FAOD lab values, and 5) a need for more improved treatment options. A newer therapy, triheptanoin, is in late-stage development and has already demonstrated improved outcomes compared to conventional medium-chain triglyceride (MCT) treatment in clinical trials.
This webinar, Breaking Down Long-Chain Fatty Acid Oxidation Disorder Treatment: Review of Current Care and the Latest Advances, will help metabolic clinicians better assess and manage LC-FAOD and educate their patients to encourage adherence to treatment.
Welcome and Introduction
Ensuring Optimal LC-FAOD Management
Metabolic Clinician Considerations for LC-FAOD Management
Understanding the Promising LC-FAOD Therapies in Late-Stage Development
Q&A Session and Activity Roundup
Melanie Gillingham, PhD, RD
Department of Molecular and Medical Genetics
Oregon Health and Science University
Jerry Vockley, MD, PhD
Professor of Pediatrics and Cleveland Family
Endowed Chair in Pediatric Research, University of Pittsburgh School of Medicine
Professor of Human Genetics, Graduate School of Public Health
Chief of Medical Genetics
Director, Center for Rare Disease Therapy
Children’s Hospital of Pittsburgh
This activity is intended for metabolic clinicians (metabolic physicians, NPs, nurses, and dietitians) who manage patients with LC-FAODs.
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
- Create personalized treatment plans for patients with LC-FAODs, incorporating the latest clinical evidence and expert recommendations
- Identify metabolic clinician-led tactics to better ensure adherence to LC-FAOD therapy
- Evaluate clinically relevant lab values to personalize LC-FAOD management
- Evaluate the safety and efficacy data with the promising treatments in late-stage trials for LC-FAOD
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Rockpointe. The Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN DESIGNATION STATEMENT
The Penn State College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through PSU’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
CDR DESIGNATION STATEMENT
This program is acceptable for a maximum of 1.0 CPEU Level 2 credits from the Commission on Dietetic Registration.
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Penn State College of Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosures will be made known to participants prior to the activity.
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must register, view the live activity in its entirety, then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certific
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
Jointly provided by Penn State College of Medicine and Rockpointe
This program is supported by an educational grant from Ultragenyx Pharmaceutical Inc.